drugset / Trial / NCT06282159
A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with generalized myasthenia gravis (gMG).
Timeline
- Start
- 2024-02-23
- Primary completion
- 2025-07-28
- Completion
- 2028-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Claseprubart | Unknown | 300 mg | Intravenous |
| Subject | Claseprubart | Unknown | 600 mg | Intravenous |